PHASE-II EVALUATION OF BISANTRENE IN REFRACTORY MULTIPLE-MYELOMA - A SOUTHWEST ONCOLOGY GROUP-STUDY

被引：0
|
作者：
DURIE, BGM
CROWLEY, J
COLTMAN, CA
CHAPMAN, RA
BALCERZK, SP
BONNET, JD
LIPSCHITZ, DA
STEPHENS, RL
CHESON, BD
机构：
[1] UNIV ARKANSAS MED SCI HOSP,LITTLE ROCK,AR 72205
[2] UNIV KANSAS,MED CTR,KANSAS CITY,KS 66103
[3] UNIV UTAH,MED CTR,SALT LAKE CITY,UT 84112
[4] UNIV ARIZONA,CTR CANC,TUCSON,AZ 85721
[5] SW ONCOL GRP,CTR STAT,SEATTLE,WA
[6] UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX 78284
[7] HENRY FORD HOSP,DETROIT,MI 48202
[8] OHIO STATE UNIV,CTR HLTH,COLUMBUS,OH 43210
[9] SCOTT & WHITE MEM HOSP & CLIN,TEMPLE,TX
来源：
INVESTIGATIONAL NEW DRUGS | 1991年 / 9卷 / 04期
关键词：
BISANTRENE; MYELOMA;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：329 / 331
页数：3
相关论文
共 50 条
  • [21] PHASE-II STUDY OF SPIROGERMANIUM IN ADVANCED ADENOCARCINOMA OF THE PROSTATE - A SOUTHWEST ONCOLOGY GROUP-STUDY
    SAIERS, JH
    BLUMENSTEIN, B
    SLAVIK, M
    COSTANZI, JH
    CRAWFORD, ED
    CANCER TREATMENT REPORTS, 1987, 71 (12): : 1305 - 1306
  • [22] BISANTRENE HYDROCHLORIDE IN GASTRIC ADENOCARCINOMA - A SOUTHWEST ONCOLOGY GROUP-STUDY
    PANETTIERE, FJ
    JONES, SE
    OISHI, N
    EYRE, HJ
    OBRYAN, RM
    ANDES, WA
    TAYLOR, SA
    GROZEA, PN
    MEDICAL AND PEDIATRIC ONCOLOGY, 1986, 14 (02): : 78 - 80
  • [23] PHASE-II STUDY OF PIBENZIMOL IN PANCREATIC-CANCER - A SOUTHWEST ONCOLOGY GROUP-STUDY
    KRAUT, EH
    FLEMING, T
    SEGAL, M
    NEIDHART, JA
    BEHRENS, BC
    MACDONALD, J
    INVESTIGATIONAL NEW DRUGS, 1991, 9 (01) : 95 - 96
  • [24] PHASE-II STUDY OF MITOGUAZONE IN PANCREATIC-CANCER - A SOUTHWEST ONCOLOGY GROUP-STUDY
    INAMASU, MS
    OISHI, N
    CHEN, TT
    KRAUT, EH
    GROZEA, PN
    COSTANZI, JJ
    BONNET, JD
    CANCER TREATMENT REPORTS, 1986, 70 (04): : 531 - 532
  • [25] PHASE-II STUDY OF AMSACRINE IN GASTRIC-CARCINOMA - A SOUTHWEST ONCOLOGY GROUP-STUDY
    INAMASU, M
    OISHI, N
    CHEN, TT
    HICKS, WJ
    OBRYAN, RM
    CANCER TREATMENT REPORTS, 1985, 69 (05): : 557 - 558
  • [26] IMPROVED SURVIVAL DURATION WITH COMBINATION CHEMOTHERAPY INDUCTION FOR MULTIPLE-MYELOMA - A SOUTHWEST ONCOLOGY GROUP-STUDY
    DURIE, BGM
    DIXON, DO
    CARTER, S
    STEPHENS, R
    RIVKIN, S
    BONNET, J
    SALMON, SE
    DABICH, L
    FILES, JC
    COSTANZI, JJ
    JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (08) : 1227 - 1237
  • [27] PHASE-II EVALUATION OF DIDEMNIN-B IN ADVANCED ADENOCARCINOMA OF THE KIDNEY - A SOUTHWEST ONCOLOGY GROUP-STUDY
    TAYLOR, SA
    GOODMAN, P
    CRAWFORD, ED
    STUCKEY, WJ
    STEPHENS, RL
    GAYNOR, ER
    INVESTIGATIONAL NEW DRUGS, 1992, 10 (01) : 55 - 56
  • [28] PHASE-II EVALUATION OF FTORAFUR IN PREVIOUSLY UNTREATED COLORECTAL-CANCER - SOUTHWEST ONCOLOGY GROUP-STUDY
    BUROKER, T
    PADILLA, F
    GROPPE, C
    GUY, G
    QUAGLIANA, J
    MCCRACKEN, J
    VAITKEVICIUS, VK
    HOOGSTRATEN, B
    HEILBRUN, L
    CANCER, 1979, 44 (01) : 48 - 51
  • [29] A PHASE-II EVALUATION OF IFOSFAMIDE AND MESNA IN UNRESECTABLE DIFFUSE MALIGNANT MESOTHELIOMA - A SOUTHWEST ONCOLOGY GROUP-STUDY
    ZIDAR, BL
    METCH, B
    BALCERZAK, SP
    PIERCE, HI
    MILITELLO, L
    KEPPEN, MD
    BERENBERG, JL
    CANCER, 1992, 70 (10) : 2547 - 2551
  • [30] PHASE-II EVALUATION OF ANGUIDINE IN CENTRAL NERVOUS-SYSTEM TUMORS - A SOUTHWEST ONCOLOGY GROUP-STUDY
    GOODWIN, JW
    BOTTOMLEY, RH
    VAUGHN, CB
    FRANK, J
    PUGH, RP
    CANCER TREATMENT REPORTS, 1983, 67 (03): : 285 - 286
12345